Lindis Biotech GmbH announced a licensing agreement with global pharmaceutical company Pharmanovia for catumaxomab, for the treatment of malignant ascites.
ARC, the innovation arm of Sheba Medical Center Israel’s largest hospital and a global leader in clinical trials, announced today a collaboration with Roche, a leading provider of digital pathology solutions worldwide, to help improve the diagnosis and treatment of non-small cell lung cancer.Â
Immunai Inc. announced a multi-year collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd. Under the agreement, Immunai will collaborate with Teva in immunology and Immuno-oncology programs.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.
Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.Â
The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.Â
Nicole D. Fleming has joined Fred Hutch Cancer Center as the new deputy chief medical officer. Fleming brings expertise as a doctor, surgeon, researcher, administrator, mentor, and mother of three school-age children that fits well with the mission of a recently merged organization coping with growing pains.
